Comparative Pharmacology
Head-to-head clinical analysis: BREVICON 28 DAY versus BRIELLYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVICON 28 DAY versus BRIELLYN.
BREVICON 28-DAY vs BRIELLYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation. Additionally, alters cervical mucus consistency and endometrial lining to impede sperm penetration and implantation.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
One tablet (0.5 mg norethindrone and 35 mcg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 inert tablets).
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
None Documented
None Documented
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-27 hours; half-life for ethinyl estradiol allows once-daily dosing
12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment
Renal: ~40% as metabolites and unchanged drug; fecal/biliary: ~60% as metabolites
Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination
Category C
Category C
Oral Contraceptive
Oral Contraceptive